1 Although endotoxaemia induces kinin B 1 receptors in several animal models, this condition is not documented in primates. This study examined the up-regulation of haemodynamic and proin¯ammatory responses to the B 1 agonist des-Arg 10 -kallidin (dKD) in a non-human primate model. 2 Green monkeys (Cercopithecus aethiops St Kitts) received lipopolysaccharide (LPS; 90 mg kg 71 ) or saline intravenously. After 4 h, anaesthetized monkeys were canulated via the carotid artery to monitor blood pressure changes following intra-arterial injections of dKD or the B 2 agonist bradykinin (BK). Oedema induced by subcutaneous kinin administration was evaluated as the increase in ventral skin folds in anaesthetized monkeys injected with captopril at 4 h to 56 days post-LPS. 3 LPS increased rectal temperature but did not aect blood pressure after 4 h. dKD reduced blood pressure (E max : 27+4 mmHg; EC 50 : 130 pmol kg
Introduction
B 1 receptors for kinins are considered potential therapeutic targets for the development of novel therapies aimed at controlling complications of septicemia and in¯ammation Marceau et al., 1998) . Responses mediated by kinin B 1 receptors are up-regulated from a null level following administration of bacterial lipopolysaccharide (LPS) or in¯ammatory cytokines in rabbits, rats and pigs . In these models, systemic stimulation of B 1 receptors reduces blood pressure. Induction followed by local stimulation of B 1 receptors promotes oedema and hyperalgesia associated with chronic in¯ammation in the rat skin and joints Belichard et al., 2000) . In human isolated tissues, B 1 receptors appear to follow a similar pattern of up-regulation with injury or immune activation . However, current evidence suggesting B 1 receptor up-regulation in primates in vivo is limited. A recent study documented enhanced B 1 receptor mRNA expression and B 1 receptor-dependent chemotaxis in peripheral T lymphocytes isolated from patients with active multiple sclerosis as compared to non-aected individuals (Prat et al., 1999) . Thus, the aim of this study was to determine whether bacterial lipopolysaccharide (LPS) administration enhances the sensitivity to a selective B 1 agonist in a non-human primate model, namely green monkeys. Acute regulation of blood pressure and oedema induction by B 1 receptors were chosen as relevant endpoints in this model because of the potential of B 1 antagonists in the treatment of cardiovascular and in¯ammatory disorders.
tees of the CR-CHUM (Montreal, Canada) and of Caribbean Primates Ltd. (St Kitts, West Indies). Animals weighing 6.0+0.5 kg (n=67) were anaesthetized (50 mg ketamine kg
71
) and pretreated with a single intravenous injection of LPS (90 mg kg 71 ) or saline (1 ml) via the saphenous vein.
Blood pressure studies
At 4 h after pre-treatment, monkeys were anaesthetized again as described above, for haemodynamic measurements. Pressure data were acquired using a pressure transducer (Harvard Apparatus) connected to a Macintosh PowerBook G3 running the BioPac data acquisition software. The left common carotid artery was canulated and the changes in mean blood pressure were monitored in response to intraarterial bolus injections of vehicle (100 ml saline), dKD (1 ± 10 000 pmol kg 71 ) or BK (1 ± 1000 pmol kg
71
). All injections (saline or peptide), which were given at 1 ± 3 min intervals, were immediately followed by saline (300 ml) to ensure delivery of the bolus. In a subset of LPS-treated animals, the haemodynamic response to dKD (1 nmol kg
) and BK (0.1 nmol kg 71 ) were measured during and 5 min after a continuous intravenous infusion of the B 1 selective antagonist [Leu 9 ]dKD (75 nmol kg 71 min 71 via the saphenous vein). In these animals, rectal temperature was measured immediately after induction of anaesthesia, i.e. before and at 4 h after LPS or saline injection.
Inflammation studies
Kinin-induced oedema was evaluated by the ventral skin fold assay (Sciberras et al., 1987) in a separate subset of anaesthetized monkeys injected with captopril (1 mg kg 71 30 min before assay). A single subcutaneous injection of dKD, BK or the vehicle (2 mM amastatin in 100 ml Ringer's lactate) was given in the ventral area and the increase in thickness of skin folds was monitored for 30 ± 45 min using a calibrated caliper. The results were expressed as the dierence between the skin fold thickness before and after the subcutaneous injection. Captopril and amastatin were used to reduce degradation of kinins at the carboxyl-and aminoterminus, respectively. The time course after LPS for oedema induction by dKD (50 nmol) was determined at 4, 24 and 48 h, 12 and 56 days after LPS administration. BK (100 nmol) was used as a positive control. In following experiments, the dose-response relationship for dKD (1 ± 150 nmol)-induced oedema was determined at 24 h post-LPS. A dose-response curve was obtained in each monkey studied by injecting peptides at dierent sites in the ventral area. To document inhibition of oedema formation by a B 1 receptor antagonist, [Leu 9 ]dKD (150 nmol) was co-injected or not with dKD (50 nmol) at 24 h post-LPS. Rectal temperature was measured in anaesthetized animals before and up to 56 days after LPS injection. Animals were used only once throughout these studies.
Drugs
Ketamine hydrochloride, LPS, amastatin and captopril were from Sigma (MO, U.S.A.). All peptides were from Phoenix Pharmaceuticals (CA, U.S.A.).
Statistics
Values are presented as mean+standard error of the mean (s.e.mean). In oedema studies, the pre-injection thickness of the skin folds was subtracted from the values after subcutaneous challenge. Curve ®tting and EC 50 calculations were obtained using the Delta Graph 4.0 software for Apple Computers. Data were compared by two-way analysis of variance followed by unpaired, one tail Student's t-test with Bonferroni correction. P50.05 was considered statistically signi®cant.
Results
LPS injection induced a signi®cant increase in rectal temperature after 4 h (38.5+0.28C; n=15) as compared to pre-LPS values (37.7+0.28C; P50.05) or values in salinetreated monkeys (data not shown). Rectal temperature remained elevated at 24 h (38.4+0.38C; n=6) but not 48 h after LPS (37.7+0.28C; n=8). At 4 h, LPS pretreatment did not aect mean blood pressure (112+10 mmHg; n=12) as compared to saline-treated animals (112+10 mmHg; n=5).
Blood pressure regulation by kinins
Administration of dKD at 4 h dose-dependently reduced blood pressure in monkeys pretreated with LPS (EC 50 : 130 pmol kg 71 ) but had a marginal eect in salinepretreated animals ( Figure 1a ). In contrast, BK dosedependently reduced blood pressure in monkeys pretreated with saline or LPS, with no dierence between experimental groups ( Figure 1b ). There was no evidence that the maximal eect of BK was attained at the highest dose administered (1 nmol kg
71
). Figure 2 shows a blood pressure tracing obtained at 4 h in an LPS-treated animal. The maximal hypotensive response was attained at 21+3 s in response to dKD (1 nmol kg 71 ) and 17+2 s for BK (1 nmol kg
, not signi®cantly dierent from dKD). At these time points, dKD and BK decreased blood pressure and increased heart rate similarly (control values for heart rate: 157+3 and 153+4 b.p.m., respectively; Figure 3 ). However, these eects were longer lasting with dKD (41 min) than BK (41 min 
Discussion
A growing body of evidence suggests a role for kinin B 1 receptors in immunopathology, particularly in promoting chronic in¯ammatory disorders . In contrast with kinin B 2 receptors, current evidence suggests that B 1 receptor-mediated cardiovascular or in¯ammatory responses are normally low or absent in humans, rabbits and rats Marceau et al., 1998; Prat et al., 1999) . To date, constitutive B 1 receptor expression has been documented in vascular tissues of dogs Staszewska-Woolley & Woodman, 1991) , the central nervous system of spontaneously hypertensive rats (Emanueli et al., 1999) , the hindlimb and pulmonary vasculature in cats (Santiago et al., 1995; Seyedi et al., 1997) and human ocular tissues (Ma et al., 1996) and T lymphocytes (Prat et al., 1999) . Factors implicated in B 1 receptor induction include bacterial endotoxin, pro-in¯am- matory cytokines (e.g., interleukin-1) as well as intracellular pathways regulating the cell response to environmental stress (e.g., the p38 MAP kinase and NF-kB pathways) (Bastian et al., 1998; Larrivee et al., 1998; Marceau et al., 1998; Phagoo et al., 1999; Prat et al., 1999; Sardi et al., 1998; Tsukagoshi et al., 1999) . In turn, B 1 receptor stimulation may activate further these same pathways (Campos et al., 1999; Naraba et al., 1998; Schanstra et al., 1998; Tsukagoshi et al., 1999) . B 1 receptors may also interact with cytokines to promote further B 1 receptor up-regulation (Phagoo et al., 1999) . The role of B 1 receptors during haemodynamic disorders associated with septicaemia is still unclear (Siebeck et al., 1996) . However, studies in rodent models of in¯ammation have provided fairly convincing evidence implicating B 1 receptors as mediators of chronic oedema and hyperalgesia in the skin and joints . By virtue of its selective induction at sites of in¯ammation, the B 1 receptor is considered a potential therapeutic target for the control of tissue response to immune activation or mechanical injury, with minimal secondary eects in non-aected tissues. To date, however, there is no primate model of in vivo B 1 receptor sensitization. Moreover, it remains unclear whether B 1 agonists are proin¯ammatory in these species, although the enhanced B 1 receptor-mediated migration shown by T lymphocytes from patients with active multiple sclerosis (Prat et al., 1999) support this hypothesis.
Functional studies of human B 1 receptor sensitization in the cardiovascular system come in large part from in vitro studies with cultured cells or incubated smooth muscle preparations . To our knowledge, the present study in green monkeys provides the ®rst evidence that endotoxin up-regulates B 1 receptor-mediated responses in primates in vivo, a condition associated with increased haemodynamic and pro-in¯ammatory responses to a selective B 1 agonist. This interpretation is based on three lines of observations. (1) dKD induced signi®cant, dose-dependent haemodynamic or in¯ammatory responses only in LPSpretreated monkeys. (2) The increased sensitivity to kinins was speci®c for dKD (responses to BK were signi®cant in control monkeys and unaected after LPS). (3) The selective B 1 antagonist dLKD inhibited the responses to dKD. Although supportive molecular evidence has not been obtained in monkeys, the present functional evidence is compatible with the notion that LPS increased tissue expression of the B 1 receptor gene in sensitized tissues, as shown in rats and rabbits (Marceau et al., 1999; MarinCastano et al., 1998; McLean et al., 1999) . Beside LPS, several other conditions known to up-regulate sensitivity to B 1 agonists are also associated with increased B 1 receptor mRNA levels (Bastian et al., 1998; Belichard et al., 1999; Phagoo et al., 1999; Prat et al., 1999; Tsukagoshi et al., 1999) . Notably, increased B 1 gene expression and biological activity were recently observed in a model of in¯ammatory hyperalgesia induced by zymosan injection in the plantar tissue of the rat (Belichard et al., 2000) . Based on current data (Davis et al., 1996; Marceau et al., 1998; McLean et al., 2000) , candidate cell types expressing functional B 1 receptors in LPS-treated monkeys include endothelial cells, vascular smooth muscle cells, ®broblasts, mast cells and peripheral sensory neurons.
The haemodynamics eects of B 1 receptor agonists are complex and may involve the modulation of cardiac contractility and vasodilatation following the release of prostaglandins or nitric oxide depending on the species and vascular bed. In conscious instrumented dogs under ganglionic blockade, infusion of des-Arg 9 -BK or BK reduces mean arterial pressure and coronary vascular resistance without changing cardiac contractility . In contrast, both cardiac contractility and arterial pressure are reduced (even under ganglionic blockade) in response to B 1 receptor stimulation in rabbits anaesthetized following LPS pretreatment (Audet et al., 1997) . In anaesthetized monkeys however, kinin-induced tachycardia was evident, an eect that was signi®cantly more sustained with the B 1 agonist. These dierences may depend on the species or experimental conditions such as the type of anaesthesia used. Possible mechanisms for kinin-induced tachycardia in monkeys include re¯ex sympathetic activation in response to the fall in blood pressure, and pre-synaptic stimulation of catecholamine release as shown in rats, guinea-pigs and cats following stimulation with a B 2 agonist (Kurz et al., 1997; Loro et al., 1998; Seyedi et al., 1997) or a B 1 agonist (DeWitt et al., 1994) . Vascular B 1 receptors coupled to nitric oxide release mediate relaxation in bovine (Drummond & Cocks, 1995) , porcine and human (Su et al., 2000) coronary arteries, rabbit carotid arteries (Pruneau & Belichard, 1993) and cat pulmonary arteries (DeWitt et al., 1994) . Alternatively, B 1 receptors coupled to prostaglandin release mediate vascular relaxation in rabbit mesenteric arteries (deBlois & Marceau, 1987) , rabbit coeliac arteries (Ritter et al., 1989) , dog mesenteric veins (Toda et al., 1987) and rat coronary arteries (McLean et al., 1999) . Proposed mechanisms for kinin-induced vasorelaxation also include the ]dKD was co-injected with dKD. * Signi®cantly dierent (P50.05) from response without [Leu release of endothelial hyperpolarizing factor(s) (Mombouli et al., 1992) . In dogs and LPS-treated rabbits, inhibition of prostaglandin or nitric oxide production does not elicit a marked reduction in maximal hypotensive response to B 1 receptor stimulation (Audet et al., 1997; Belichard et al., 1996) . The duration of the hypotension is reduced, however, by cyclo-oxygenase inhibition in rabbits (Audet et al., 1994; Drapeau et al., 1991) , suggesting a signi®cant haemodynamic role for prostaglandins. Based on these data, it is dicult to speculate on the possible role of the cyclo-oxygenase and nitric oxide pathways in B 1 receptor-mediated hypotensive responses in monkeys, although a role for reduced cardiac output can be ruled out.
The present results are consistent with observations made in rat models of oedema development (Campos et al., 1996; 1997; de Campos et al., 1998) . At 24 h following systemic administration of LPS in rats, intra-plantar administration of des-Arg (Campos et al., 1996) . Injection of rats with Mycobacterium bovis bacillus Calmette-Guerin results in longterm sensitization to B 1 agonists in the paw oedema assay (for up to 75 days) (Campos et al., 1997) . Although no live bacteria were used in monkeys, B 1 sensitization in the skin was sustained for up to 12 days (but less than 56 days) following LPS. In contrast, the pyrogenic response to LPS lasted less than 2 days. Together, these data suggest a slow rate of receptor turnover in vivo, a feature consistent with known characteristics of B 1 receptors which include lack of ligand-induced receptor desensitization and sequestration (Faussner et al., 1999) . A role for prostaglandins in the present model is likely. Pro-in¯ammatory prostaglandins were implicated in mediating B 1 receptor-induced oedema in rats (Campos & Calixto, 1995; Campos et al., 1996) . Moreover, several studies showed B 1 receptor activation of the cyclo-oxygenase pathway in vascular cells or ®broblasts (Lerner & Modeer, 1991; Marceau et al., 1998) . New, potent, peptide and non-peptide antagonists of B 1 receptors are being developed, with in¯ammation-associated hyperalgesia as a primary target condition (Altamura et al., 1999; Galoppini et al., 1999; Gobeil et al., 1999; Horlick et al., 1999) . The observation that dKD mediates oedema in green monkeys supports the assumption that B 1 receptor antagonists may be eective anti-in¯ammatory tools in humans. In non-human primates, B 1 receptor-induced oedema may oer a simple and ethical surrogate assay for B 1 -mediated hyperalgesia.
Several studies provided evidence that the structurerelationship of B 1 antagonists is species-dependent (MacNeil et al., 1997; Nsa Allogho et al., 1998; Wohlfart et al., 1997) . Notably, peptide B 1 antagonists such as [Leu 8 ]-des-Arg 9 -BK act as partial agonists on the murine B 1 receptor (MacNeil et al., 1997; Nsa Allogho et al., 1998) . In hexamethoniumtreated dogs, administration of [Leu
